BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Authors » Diana Tucker

Articles by Diana Tucker

New imaging modalities focus on breast cancer

Dec. 7, 2010
By Diana Tucker

How to treat high platelet reactivity: still confusing

Nov. 22, 2010
By Diana Tucker

PFO/stroke connection remains perplexing medical conundrum

Nov. 17, 2010
By Diana Tucker
CHICAGO — Sometimes logic and anecdotal information just can't connect the dots. Such was the case with the long-awaited CLOSURE 1 randomized controlled clinical trial results to evaluate the safety and efficacy of NMT Medical's (Boston) STARFlex septal closure system that were reported this week at the American Heart Association (AHA; Dallas) 2010 Scientific Sessions. (Medical Device Daily)
Read More

Can advanced surgical technologies survive in today's economy?

Nov. 1, 2010
By Diana Tucker

Newest research shows some surgeries no longer necessary

Oct. 8, 2010
By Diana Tucker

AAD meeting shows laser procedures are a girl's new best friend

Oct. 1, 2010
By Diana Tucker

No algorithm for selecting appropriate bariatric procedure for specific patient

Aug. 1, 2010
By Diana Tucker

NOTES goes from experimental to investigational with trial

July 23, 2010
By Diana Tucker
CHICAGO – The initial excitement and big buzz about Natural Orifice Translumenal Endoscopic Surgery®(NOTES) has been replaced with the heavy lifting of entering hard, long clinical trials that carefully evaluate the potential benefits and risks associated with the novel technique. The 5th meeting of the Natural Orifice Surgery Consortium for Assessment and Research® (NOSCAR) was held here with exciting news of initial human trials being performed. (Medical Device Daily)
Read More

Advanced laparascopic surgery: A blended mix of new technologies

May 1, 2010
By Diana Tucker

Surgeon scientists becoming advocates of cancer patients

March 30, 2010
By Diana Tucker
Chicago — With a backdrop of the newly passed Healthcare Reform Bill, cancer surgeons whose practices may be altered forever, met here for the advancement of pure science and humanitarianism. The objective of the American College of Surgeons Oncology Group (ACOSOG; Durham, North Carolina) is to study cancer patient outcomes using clinical trials as a measure for new advanced methods in order to further advance patient care. (Medical Device Daily)
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing